Oscient To Pursue Factive Sinusitis Claim Despite FDA Refusal To File
This article was originally published in Pharmaceutical Approvals Monthly
Oscient will pursue potential paths to file its antibiotic Factive for a supplemental indication to treat acute bacterial sinusitis after FDA refused to review its initial sNDA
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class